You can access the original SEC filing by clicking here.
Ownership Summary Table
| Name | Sole Voting Power | Shared Voting Power | Sole Dispositive Power | Shared Dispositive Power | Aggregate Amount Owned Power | Percent of Class |
|---|---|---|---|---|---|---|
| Alan W. Schoenbart | 774,500 | 0 | 774,500 | 0 | 774,500 | 5.6% |
Page 1 of 4 – SEC Filing
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13D
(Rule 13d – 102)
INFORMATION TO BE INCLUDED IN STATEMENTS FILED
PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED
PURSUANT
TO RULE 13d-2(a)
ECHO
THERAPEUTICS, INC.
THERAPEUTICS, INC.
(Name of Issuer)
Common
Stock, par value $.01 per share
Stock, par value $.01 per share
(Title of Class of Securities)
27876L107
(CUSIP Number)
Kevin
W. Waite, Esq.
W. Waite, Esq.
Moomjian,
Waite, Wactlar & Coleman, LLP
Waite, Wactlar & Coleman, LLP
100
Jericho Quadrangle, Suite 208
Jericho Quadrangle, Suite 208
Jericho,
New York 11753
New York 11753
(516)
937-5900
937-5900
(Name, Address and Telephone Number of Person Authorized
to
Receive Notices and Communications)
March
21, 2017
21, 2017
(Date of Event which Requires Filing of this
Statement)
If the
filing person has previously filed a statement on Schedule 13G to
report the acquisition that is the subject of this Schedule 13D,
and is filing this schedule because of Rule 13d-1(e), 13d-1(f), or
13d-1(g), check the following box [ ].
filing person has previously filed a statement on Schedule 13G to
report the acquisition that is the subject of this Schedule 13D,
and is filing this schedule because of Rule 13d-1(e), 13d-1(f), or
13d-1(g), check the following box [ ].
NOTE:
Schedules filed in paper format shall include a signed original and
five copies of the schedule, including all exhibits. See Rule
13d-7(b) for other parties to whom copies are to be
sent.
Schedules filed in paper format shall include a signed original and
five copies of the schedule, including all exhibits. See Rule
13d-7(b) for other parties to whom copies are to be
sent.
*The
remainder of this cover page shall be filled out for a reporting
person’s initial filing on this form with respect to the subject
class of securities, and for any subsequent amendment containing
information which would alter disclosure provided in a prior cover
page.
remainder of this cover page shall be filled out for a reporting
person’s initial filing on this form with respect to the subject
class of securities, and for any subsequent amendment containing
information which would alter disclosure provided in a prior cover
page.
The
information required on the remainder of this cover page shall not
be deemed to be “filed” for the purpose of Section 18
of the Securities Exchange Act of 1934 (“Act”) or
otherwise subject to the liabilities of that Section of the Act but
shall be subject to all other provisions of the Act (however, see
the Notes).
information required on the remainder of this cover page shall not
be deemed to be “filed” for the purpose of Section 18
of the Securities Exchange Act of 1934 (“Act”) or
otherwise subject to the liabilities of that Section of the Act but
shall be subject to all other provisions of the Act (however, see
the Notes).
Follow Echo Therapeutics Inc. (NASDAQ:ECTE)
Follow Echo Therapeutics Inc. (NASDAQ:ECTE)
We may use your email to send marketing emails about our services. Click here to read our privacy policy.
Page 2 of 4 – SEC Filing
CUSIP
No. 27876L107
No. 27876L107
Page 2 of 4
Pages
Pages
1 NAMES
OF REPORTING PERSONS
OF REPORTING PERSONS
I.R.S.
IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)
IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)
Alan
W. Schoenbart
W. Schoenbart
_________________________________________________________________________________
2 CHECK
THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See
Instructions)
THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See
Instructions)
(a) [
]
]
(b) [
]
]
_________________________________________________________________________________
3 SEC
USE ONLY
USE ONLY
_________________________________________________________________________________
4
SOURCE OF FUNDS (See Instructions)
SOURCE OF FUNDS (See Instructions)
OO
_________________________________________________________________________________
5 CHECK
BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO
ITEMS
BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO
ITEMS
2(d)
OR 2(e) [ ]
OR 2(e) [ ]
_________________________________________________________________________________
6
CITIZENSHIP OR PLACE OF ORGANIZATION
CITIZENSHIP OR PLACE OF ORGANIZATION
United
States of America
States of America
| NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH | 7 SOLE VOTING POWER 774,500 (1) |
| 8 SHARED VOTING POWER 0 | |
| 9 SOLE DISPOSITIVE POWER 774,500 (1) | |
| 10 SHARED DISPOSITIVE POWER 0 |
11
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING
PERSON
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING
PERSON
774,500
(1)
(1)
_________________________________________________________________________________
12
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN
SHARES
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN
SHARES
(See Instructions)
[ ]
[ ]
_________________________________________________________________________________
13
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
5.6%
_________________________________________________________________________________
14 TYPE
OF REPORTING PERSON (See Instructions)
OF REPORTING PERSON (See Instructions)
IN
_________________________________________________________________________________
(1)
Includes 600,000
shares underlying currently exercisable stock options.
shares underlying currently exercisable stock options.
Follow Echo Therapeutics Inc. (NASDAQ:ECTE)
Follow Echo Therapeutics Inc. (NASDAQ:ECTE)
We may use your email to send marketing emails about our services. Click here to read our privacy policy.
Page 3 of 4 – SEC Filing
Item 1. Security and Issuer.
The
class of securities to which this statement relates is the common
stock, par value $0.01 per share (the “Common Stock”),
of Echo Therapeutics, Inc. (the “Company”). The
Company’s principal executive offices are located at 99 Wood
Avenue South., Suite 302, Iselin, NJ 08830.
class of securities to which this statement relates is the common
stock, par value $0.01 per share (the “Common Stock”),
of Echo Therapeutics, Inc. (the “Company”). The
Company’s principal executive offices are located at 99 Wood
Avenue South., Suite 302, Iselin, NJ 08830.
Item 2. Identity and Background.
(a)
This statement is being filed by Alan W. Schoenbart, the Chief
Executive Officer, Chief Financial Officer and director of the
Company.
This statement is being filed by Alan W. Schoenbart, the Chief
Executive Officer, Chief Financial Officer and director of the
Company.
(b) The
business address for Mr. Schoenbart is c/o Echo Therapeutics, Inc.,
99 Wood Avenue South., Suite 302, Iselin, NJ 08830.
business address for Mr. Schoenbart is c/o Echo Therapeutics, Inc.,
99 Wood Avenue South., Suite 302, Iselin, NJ 08830.
(c) Mr.
Schoenbart is the Chief Executive Officer, Chief Financial Officer
and director of the Company. The address for the Company is set
forth above in Item 1.
Schoenbart is the Chief Executive Officer, Chief Financial Officer
and director of the Company. The address for the Company is set
forth above in Item 1.
(d) Mr.
Schoenbart has not, during the last five years, been convicted in a
criminal proceeding (excluding traffic violations or similar
misdemeanors).
Schoenbart has not, during the last five years, been convicted in a
criminal proceeding (excluding traffic violations or similar
misdemeanors).
(e) Mr.
Schoenbart has not, during the last five years, been a party to a
civil proceeding of a judicial or administrative body of competent
jurisdiction and was or is not as a result of such proceeding
subject to a judgment, decree or final order enjoining future
violations of, or prohibiting or mandating activities subject to,
federal or state securities laws or finding any violation with
respect to such laws.
Schoenbart has not, during the last five years, been a party to a
civil proceeding of a judicial or administrative body of competent
jurisdiction and was or is not as a result of such proceeding
subject to a judgment, decree or final order enjoining future
violations of, or prohibiting or mandating activities subject to,
federal or state securities laws or finding any violation with
respect to such laws.
(f) Mr.
Schoenbart is a citizen of the United States.
Schoenbart is a citizen of the United States.
Item 3. Source and Amount of Funds or Other
Consideration.
The
response to Item 4 is incorporated herein by
reference.
response to Item 4 is incorporated herein by
reference.
Item
4.
4.
Purpose
of Transaction
of Transaction
On
March 21, 2017, in connection with his appointment as Chief
Executive Officer, the Company granted to Mr. Schoenbart an option
(“Option”) to purchase 500,000 shares of Common Stock
pursuant to the Company’s 2008 Equity Incentive Plan. The
Option has a term of 10 years, an exercise price of $0.16 per
share, the closing price of the Common Stock on the date of grant,
and vested in full immediately on grant. Mr. Schoenbart was also
granted 100,000 restricted shares of Common Stock pursuant to the
Company’s 2008 Equity Incentive Plan, which shares vested in
full immediately on grant.
March 21, 2017, in connection with his appointment as Chief
Executive Officer, the Company granted to Mr. Schoenbart an option
(“Option”) to purchase 500,000 shares of Common Stock
pursuant to the Company’s 2008 Equity Incentive Plan. The
Option has a term of 10 years, an exercise price of $0.16 per
share, the closing price of the Common Stock on the date of grant,
and vested in full immediately on grant. Mr. Schoenbart was also
granted 100,000 restricted shares of Common Stock pursuant to the
Company’s 2008 Equity Incentive Plan, which shares vested in
full immediately on grant.
Except
as set forth herein, the Reporting Persons has no present plan or
proposal that would relate to or result in any of the matters set
forth in subparagraphs (a)-(j) of Item 4 of Schedule
13D.
as set forth herein, the Reporting Persons has no present plan or
proposal that would relate to or result in any of the matters set
forth in subparagraphs (a)-(j) of Item 4 of Schedule
13D.
Item 5. Interest in Securities of the Issuer.
(a) The
aggregate number of shares of Common Stock beneficially owned by
the Reporting Person is 774,500, of which 600,000 shares are
underlying currently exercisable stock options. Such amount
represents beneficial ownership of 5.6% of the Common Stock of the
Company (based on 13,197,278 shares outstanding as of the date
hereof).
aggregate number of shares of Common Stock beneficially owned by
the Reporting Person is 774,500, of which 600,000 shares are
underlying currently exercisable stock options. Such amount
represents beneficial ownership of 5.6% of the Common Stock of the
Company (based on 13,197,278 shares outstanding as of the date
hereof).
(b) The
number of shares of Common Stock as to which Mr. Schoenbart
has:
number of shares of Common Stock as to which Mr. Schoenbart
has:
1. Sole
power to vote or to direct vote is 774,500.
power to vote or to direct vote is 774,500.
2.
Shared
power to vote or to direct vote is 0.
Shared
power to vote or to direct vote is 0.
3.
Sole
power to dispose or to direct the disposition is
774,500.
Sole
power to dispose or to direct the disposition is
774,500.
4.
Shared
power to dispose or to direct the disposition is 0.
Shared
power to dispose or to direct the disposition is 0.
(c) On
March 21, 2017, in connection with his appointment as Chief
Executive Officer, the Company granted to Mr. Schoenbart the Option
to purchase 500,000 shares of Common Stock and 100,000 restricted
shares of Common Stock. Other than the forgoing, Mr. Schoenbart has
not effected any transactions with respect to any securities of the
Company during the past sixty days.
March 21, 2017, in connection with his appointment as Chief
Executive Officer, the Company granted to Mr. Schoenbart the Option
to purchase 500,000 shares of Common Stock and 100,000 restricted
shares of Common Stock. Other than the forgoing, Mr. Schoenbart has
not effected any transactions with respect to any securities of the
Company during the past sixty days.
(d) Not
Applicable.
Applicable.
(e) Not
Applicable.
Applicable.
Item 6. Contracts, Arrangements, Understandings or Relationships
with Respect to the
Securities
of the Issuer
None.
Item 7. Material to be Filed as Exhibits.
None.
Follow Echo Therapeutics Inc. (NASDAQ:ECTE)
Follow Echo Therapeutics Inc. (NASDAQ:ECTE)
We may use your email to send marketing emails about our services. Click here to read our privacy policy.
Page 4 of 4 – SEC Filing
SIGNATURE
After
reasonable inquiry and to the best of my knowledge and belief, I
certify that the information set forth in this statement is true,
complete and correct.
reasonable inquiry and to the best of my knowledge and belief, I
certify that the information set forth in this statement is true,
complete and correct.
Dated:
April 5, 2017
April 5, 2017
/s/ Alan W.
Schoenbart
Schoenbart
Alan W. Schoenbart
Follow Echo Therapeutics Inc. (NASDAQ:ECTE)
Follow Echo Therapeutics Inc. (NASDAQ:ECTE)
We may use your email to send marketing emails about our services. Click here to read our privacy policy.
